LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SSII
SS Innovations International, Inc.
There isn't enough reported data to score SSII yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SSII Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
SSII's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SSII PE Valuation
SSII has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SSII Forward outlook
There aren't enough analyst estimates for SSII to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SSII on earnings quality, reporting a profit while its opponent remains loss making.
SSII Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.06 | $0.00 |
| Q1 2026 | -$0.05 | +$0.03 |
| Q4 2025 | -$0.06 | +$0.05 |
| Q3 2025 | -$0.06 | +$0.11 |
| Q2 2025 | -$0.06 | +$0.10 |
| Q1 2025 | -$0.08 | +$0.10 |
| Q4 2024 | -$0.11 | +$0.33 |
| Q3 2024 | -$0.17 | +$0.50 |
SSII is still losing money, but far less than before: $0.06 per share over the past year, against $1.60 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SSII on profitability, with a higher operating margin.
SSII Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $13.9M | +39% |
| Q1 2026 | $11.1M | +117% |
| Q4 2025 | $14.5M | +79% |
| Q3 2025 | $12.8M | +192% |
| Q2 2025 | $10M | +122% |
| Q1 2025 | $5.1M | +41% |
| Q3 2024 | $4.4M | +101% |
| Q2 2024 | $4.5M | +138% |
SSII has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -16% | -17 points |
| Q1 2026 | -33% | +83 points |
| Q4 2025 | -5.1% | +18 points |
| Q3 2025 | -14% | +59 points |
| Q2 2025 | 1% | +92 points |
| Q1 2025 | -116% | +155 points |
| Q4 2024 | -23% | N/A |
| Q3 2024 | -73% | +12 points |
SSII's operating margin was −16% last quarter, down 17 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SSII on cash generation, producing positive trailing cash flow while its opponent burns cash.
SSII Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4.2M | -$465.5K |
| Q1 2026 | -$2.4M | +$4.6M |
| Q4 2025 | -$3.2M | +$152.8K |
| Q3 2025 | -$8.2M | -$7.4M |
| Q2 2025 | -$3.8M | -$634.5K |
| Q1 2025 | -$7M | -$4.2M |
| Q4 2024 | -$3.4M | +$2.4M |
| Q3 2024 | -$844K | +$4.3M |
SSII has burned cash in almost every quarter: −$18M over the past year, against −$15M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SSII on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SSII Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +4.1M shares |
| 1 year | +3.2% | +6.6M shares |
| 3 years | +46% | +65.7M shares |
| 5 years | +9379% | +207M shares |
SSII has 209M diluted shares, up 3.2% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SSII Net Leverage
SSII's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SSII Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.7 | Oversold |
| Stochastic | 9.7 | Oversold |
SSII's weekly RSI is 22 (oversold) and its Stochastic is 10 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SSII PE vs Healthcare Sector
SSII has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has stronger trend alignment. LLY is above 5 of 5 weekly averages versus SSII above 0 of 4.
SSII Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.35 | 44% below |
| 20 week MA | $3.11 | 58% below |
| 50 week MA | $4.01 | 67% below |
| 100 week MA | $5.87 | 78% below |
SSII is in a downtrend: it's below all four of its weekly moving averages, and 78% below its 100-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SSII on returns for 2026, with the stronger performance.
SSII Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $3.75 | $8.00 | +113% |
| 2025 | $8.00 | $5.74 | -28% |
| 2026 YTD | $5.74 | $1.32 | -77% |
SSII has finished lower in one of the last two years. It's down 77% so far in 2026.